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Abstract
Natural compounds, mostly from plants, have been the mainstay of traditional medicine for thousands of years.
They have also been the source of lead compounds for modern medicine, but the extent of mining of natural
compounds for such leads decreased during the second half of the 20
th century. The advantage of natural
compounds for the development of drugs derives from their innate affinity for biological receptors. Natural
compounds have provided the best anti-malarials known to date. Recent surveys have identified many extracts of
various organisms (mostly plants) as having antiplasmodial activity. Huge libraries of fractionated natural
compounds have been screened with impressive hit rates. Importantly, many cases are known where the crude
biological extract is more efficient pharmacologically than the most active purified compound from this extract.
This could be due to synergism with other compounds present in the extract, that as such have no
pharmacological activity. Indeed, such compounds are best screened by cell-based assay where all potential targets
in the cell are probed and possible synergies identified. Traditional medicine uses crude extracts. These have often
been shown to provide many concoctions that deal better with the overall disease condition than with the
causative agent itself. Traditional medicines are used by ~80 % of Africans as a first response to ailment. Many of
the traditional medicines have demonstrable anti-plasmodial activities. It is suggested that rigorous evaluation of
traditional medicines involving controlled clinical trials in parallel with agronomical development for more
reproducible levels of active compounds could improve the availability of drugs at an acceptable cost and a
source of income in malaria endemic countries.
Background
Forty percent of the world’s population are exposed to
malaria and there is a constant need for new anti-malar-
ials in the face of the ever-present and ever-emerging
resistance of parasites to currently available drugs,
whether used in monotherapy or in combination. When
the genome of Plasmodium falciparum was first deci-
phered, there were great hopes of finding new targets
for drug development. Today, eight years later, these
hopes by no means fully materialized. Although dozens
of target-oriented compounds were shown to be anti-
plasmodial in the nanomolar range, very few of them
have reached the pre-clinical test phase [1,2]. Hence, it
seems that new approaches for the development of
antimalarial drugs should be considered, or old ones
revisited. This Introduction argues for the second of
these alternatives and to consider the potential of nat-
ural compounds for this quest.
Natural compounds were historically used as
drugs
Plants have been used as a source of medicine through-
out history and continue to serve as the basis for many
pharmaceuticals used today. The medicinal properties of
plants are described already on Assyrian clay tablets
dated about 2000 B.C. and documented in the Egyptian
culture, the Indian Ayurveda [3], in Traditional Chinese
Medicine (TCM)[4], and various European documents.
Traditional medicines not only provide valuable clues
for finding new drugs, but also may help to shift the
drug discovery paradigm from ‘finding new-entity drugs’
to ‘combining existing agents’,a n dm i g h te v e nd i r e c t
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structural comparison between ~10,000 traditional TCM
components and ~8,000 modern drugs or candidates,
identified 908 agent pairs that are structurally similar
(with similarity 0.85) and 327 agent pairs that are identi-
cal in structure. Plants continue to serve as the basis for
many pharmaceuticals used today [6]. Although the
modern pharmaceutical industry was born from botani-
cal medicine, synthetic approaches to drug discovery
have more recently become standard. Although a com-
prehensive review of human drugs introduced between
1981 and 2006 indicates that about 62 % of new small-
molecule drugs were either natural products, derived
from natural products (usually semi-synthetically) and
natural product–inspired pharmacophores (that could
be considered natural-product analogs) [6], the synthetic
combinatorial chemistry and high throughput screening
(HTS) of potential drug targets disconnected the histori-
cal link between plants and medicines. Today, however,
the small output of modern antimalarial pharmaceutical
research and development has stimulated new interest
in the potential of natural compounds.
In the pharmaceutical industry in the 1990s, the high-
throughput screening of chemical libraries against
potential targets was emphasized while, in parallel,
screening of natural product diminished. The transition
from natural sources to combinatorial libraries subjected
to high throughput screening (HTS), seem to be have
been based on the apparent advantage of rational drug
design versus “random” screening. There was perhaps
also a feeling that ethnobotany was a “soft science” and
not a scientifically valid paradigm for the discovery of
new drug leads.
Why are plants a prolific source for drugs?
One can make an argument that biologically-derived
secondary metabolites and synthetic compounds derived
from them perform better as drugs than do randomly
synthesized compounds. Primary and secondary metabo-
lites, receptors, enzymes, transporters and regulatory
proteins originated from a limited number of parent
molecules. These originating molecules were present in
primitive life forms and therefore co-evolved to interact
with one another, thus granting direct ecological benefit
to the producing organism, whether in competition for
resources, avoiding predation or combating pathogens.
Although a divergence in function and structure has
subsequently occurred, some structural relationship still
remains that make natural products, on average, better
ligands for biological targets than randomly synthesized
compounds [7,8]. Biosynthesis uses a very parsimonious
set of building blocks. It diversifies by taking its limited
battery of building blocks and distributes them into
many different pathways. Nature has a tendency to form
oxides by hydrolysis or abstraction of oxygen from
organic compounds by enzymes that delicately achieve
site-selective C–H activation to introduce oxygen and
discriminate between numerous functional groups at dif-
ferent oxidation levels. In contrast, medicinal chemistry
focuses on nitrogen and often includes additional atoms
such as sulfur and halogens that are relatively rare in
nature [9]. Generally, natural metabolites have a high
‘sterical complexity’. This is an evident outcome of the
spatial dimensionality and the chirality of the enzymes
involved in biosynthesis, their molecular targets and the
metabolites themselves [10]. Bioactive compounds share
pharmacophoric features, and natural products provide
a rich source of potentially attractive scaffolds and mole-
cular building blocks for synthesis. Since natural com-
pounds have not evolved as therapeutic agents,
sometimes their chemical structure must be further
improved, whether in terms of efficacy and selectivity
for the target or achieving optimal pharmacokinetic and
pharmacodynamic properties. The numerous ring sys-
tem scaffolds have no orthologs in the drug synthesis
database. Hence, natural products could provide new
starting points in drug discovery. The vastly unexplored
flora and fauna (90 % of total species) could provide
other new leads and drugs for chemotherapy, for the
isolation of certain natural products in large amounts,
total synthesis by chemical approaches, or limited scope
for chemical modification.
Natural compounds should be used in cell-based
assays
O n eo ft h er e a s o n sf o rt h er e l a t i v ef a i l u r eo fm o d e r n
medicine R&D in the malaria field, may be due to tech-
nological shortcomings. While target-oriented HTS is
valid for the screening of libraries of synthetic and/or
natural compounds, the underlying biochemical assays
are sometimes too sensitive and too prone to artifacts.
This arises because of issues of solubility, aggregation,
chemical reactivity and quenching effects, which detract
from the effective screening of natural extract mixtures.
To overcome these difficulties it seems preferable to use
functional biologic assays on pathogens or their host
cells, not biochemical assays on a purported target. In
the cell-based assay, all the potential targets in the cell
are screened by all compounds present in the extract
(see below for deeper discussion). There are nevertheless
several limitations facing the development of drugs from
natural sources. To name but few, many compounds
cannot be further developed because of their toxicity,
low bioavailability and/or poor solubility. Isolation of
certain natural products in large amounts may be a lim-
itation as is the limited degree for chemical modifica-
tion. The loss of plant species and habitats through
environmental change is a worry, while agriculture may
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when growth periods are long. Large-scale harvesting of
medicinal plants from forests may affect the forest ecol-
ogy or even a total extinction of the prospected species.
Synergy between constituents of crude extracts
A major difficulty in finding single-component new-
entity drugs from natural medicines originates from
the fact that the efficacy of most natural medicines
may lie in the synergy or additivity of diverse compo-
nents rather than arising from a single compound.
[11,12] The synergy of natural medicines arises from
the co-evolution between l plants and their foes [13].
For example, plants developed antimicrobials to fight
against the invasion of diverse pathogens. To survive
the antibiotic assault, pathogens evolved resistant sys-
tems, such as MDR pumps. In the next round of the
arms race, plants were stimulated to develop MDR
inhibitors [14]. Thus, a crude extract can contain both
active inhibitors and their potentiators [15]. Additive
and synergistic effects are subsets of the pharmacody-
namic of potentiation, where different compounds in a
mixture interact to provide a combined effect that is
equal to the sum of the effects of the individual com-
ponents (additive), or where combinations of bioactive
substances exert effects that are greater than the sum
of individual components (synergistic). Potentiation
can exist between different phytochemicals within a
single plant extract or with different plants or between
a phytochemical and a synthetic drug. Drug combina-
tions may produce pharmacokinetically synergistic or
antagonistic effects such that a potentiator could act
by regulating the absorption, distribution, metabolism
and excretion of the therapeutically active drug. While
pharmacodynamic interactions which occur at the cel-
lular level can be tested in vitro in cell assays, pharma-
cokinetic interactions can be identified only in vivo.
Although not a very frequent observation, cases are
reported where all the compounds found in an extract
are inactive individually but are pharmaceutically active
in combination (see Deharo and Ginsburg and Rasoa-
naivo et al,, this issue). The more common observation
is the potentiation of one active ingredient by another
inactive component. The tea prepared with Artemisia
annua on the dosage recommendations of the current
pharmacopoeia of Chinese medicine contains in total
94.5 mg/l of artemisinin, which is only 20 % of the
usually recommended daily dose in conventional treat-
ment. In conformity with this, it was demonstrated
that of the 36 flavonoids produced by A. annua,f i v e
(artemetin, casticin, chrysoplenetin, cirsilineol and
chrysosplenol-D), potentiate the in vitro activity of
artemisinin against P. falciparum, while having almost
no activity on their own [16-18]
Experimental studies have shown synergy between the
various Cinchona alkaloids (quinidine, cinchonine and
cinchonidine, all found in crude extracts of the Cinch-
ona bark) with improved activity over quinine against
resistant P. falciparum in vitro [19], particularly when
quinine is combined with cinchonine [20].
In general, synergistic and potentiative drug combina-
tions have been shown to achieve one or more favorable
results: enhanced efficacy, decreased dosage at equal or
increased level of target inhibition, reduced or delayed
development of drug resistance and simultaneous reduc-
tion of toxic effects. The mechanism of many of these
activities can be understood at the cellular level by using
network and system analyses [13]. Thus for example,
synergy may arise from interactions with an anti-target
or counter-target, from negative modulations of a net-
work’s robustness or from compensatory and neutraliz-
ing actions. Synergy can also result from complementary
actions which may involve positive regulation of a target
or process by targeting multiple points of a pathway
(such as in the case of sulphadoxine and pyrimethamine
used for malaria chemotherapy, which act on 2 different
targets of the folate biosynthesis pathway), interacting
with multiple sites, states, conformations and mutant
forms of the same target [21]. Drug combination in anti-
malarial chemotherapy is widely used [22]. It was
adopted as a strategy to prevent the evolution of resis-
tance against either component of the combination.
Importantly, it is not unlikely that the behavior of
some extracts will be significantly altered by various
interactions with the host’s metabolism and physiology,
leading either to reinforcement or to the opposite.
Developing innovative scientific methods for discovery,
validation, characterization and standardization of such
multicomponent botanical therapeutics is essential to
their acceptance into mainstream medicine [23].
Before the 20th century therapy relied almost exclu-
sively on multicomponent medicines, obtained from nat-
ural sources [24]. Presently, an increasing number of
diseases are being treated with combinations of several
single-component drugs with the aim to lower the evo-
lution of resistance or to target several pathological pro-
cesses simultaneously. They are used in treating
infectious diseases (HIV, malaria and TB) and composite
chronic diseases like cancer.
Prospecting for natural compounds
The validation of traditional remedies can be proble-
matic because of the lack of sufficient information, doc-
umentation and of standardization of extracts to be
evaluated, but these remedies deserve deep and thor-
ough consideration [25]. In spite of these problems,
such materials serve as a valuable source for novel com-
pounds. They also conceal an abundant combination of
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enhance the therapeutic effect [26,27]. Because the
quantitative and qualitative composition of secondary
metabolites in a plant is notoriously varied, standardiza-
tion is obligatory. Modern agronomic and plant genetic
methods could be harnessed to domesticate some of the
most promising medicinal plants, so as to ensure a
reproducible qualitative and quantitative production of
active ingredients, in spite of changes in biotic and abio-
tic constraints. Achieving such goals may provide indi-
genous populations in malarious areas with new
commercial crops. In addition, the road to antimalarial
development could be shortened considerably, since it is
much easier to approve the use of extracts than that of
their active ingredients. This does not mean that the use
of such extracts does not have to pass through rigorous
clinical test to assess that toxicity, teratogenicity, muta-
genicity etc are not a problem.
Natural compounds as a source for antimalarial
drugs
Research on natural compounds has already contributed
to the discovery of new antimalarial drugs. Atovaquone,
artemisinin and its semi-synthetic derivatives as well as
clindamycin, erythromycin, azithromycin, chlortetracy-
line, tetracycline, oxytetracycline and doxycycline, are
noteworthy examples of the varied contribution of nat-
ural products for the development of effective antimalar-
ial drugs, particularly valuable for the treatment of
chloroquine-resistant parasites. Several comprehensive
reviews on the antimalarial potency of plant products
derived from ethnic medicine were published in the last
decade and are summarized in Table 1. The quality of
the data used in these reviews differs and in most earlier
reports the chemical structure of the purified compound
was not known and toxicity tests were not performed.
However, in many cases good activity and selectivity
were observed. Most importantly, several compounds
containing unique structural composition have been iso-
lated and characterized. It is therefore not surprising
that natural compounds dominate the recent malaria
patent literature [28,29]. Although many compounds
cannot be further developed for reasons mentioned
above, the discovered lead compounds provide valuable
bioactive scaffolds which could be further adjusted by
semi-synthetic approaches to obtain effective anti-malar-
ials [30] See also Wells and Guantai1 & Chibale, this
issue.
Screening of natural compounds for antimalarial
activity
All this said, it could have been expected that prospect-
ing for drug leads in natural sources would systemati-
cally compare the biological activity of the extract in
parallel to that of purified compounds thereof. This is
not the case: The Eskitis Institute for Cell and Molecu-
lar Therapies has screened over 200,000 compounds
purified from 40,000 samples of plants and animals col-
lected from oceans and forests in Australia, Papua New
Guinea and China for their anti-plasmodial activity, but
has never compared their effect to that of the crude
extract from which they were purified. The same prac-
tice is ongoing in other institutes and companies such
as BioFocus DPI-UK, The University of South Florida,
Harvard Medical School and Novartis Natural Products
Unit. It is quite possible that many synergistic combina-
tions may have been missed. A thorough search of the
literature has revealed dozens of cases where the extract
has a more potent anti-plasmodial activity compared to
its most potent compound (see article by Deharo and
Ginsburg in this issue). A revision of the screening strat-
egy seems warranted.
The prospective of traditional/ethnic medicine
In some Asian and African countries, 80% of the popu-
lation depends on traditional medicine for primary
health care[31]. However, this market is plagued by
counterfeit, poor quality, or contaminated herbal pro-
ducts posing serious patient safety threats [32].
More than 100 countries have regulations for herbal
medicines. Developing innovative scientific methods for
discovery, validation, characterization and standardiza-
tion of these multicomponent botanical therapeutics is
essential to their acceptance into mainstream medicine.
Validation is limited by lack of prioritization of plant
species for research and absence of information on eth-
nobotany of these plants (location and abundance, parts
used, form of use, duration of treatment), definition of
dosages due to variation in the concentrations of active
ingredients in a plant species. It should also be stressed
that a basic requirement for the validation of a medic-
inal plant is the standardization of extracts to be evalu-
ated, including the identification and quantification of
chemical and/or biological markers to assure the devel-
opment of efficient and safe phytomedicines in a short
time and at low cost.
Testing the effects of extracts usually doesn’td i v u l g e
the drug target or its mode of action. But if the extract
is working well is it really important as to know the pre-
cise mode of action? In the context of anti-malarials, it
is relevant to underscore the fact that till this very day,
the mechanism of action of two of the most efficient
drugs derived from traditional medicine, artemisinin and
quinine, is still debatable. A search in PubMed for “tra-
ditional/ethnic and plant and malaria” retrieves 293 pub-
lications, implying that traditional herbal medicines are
a valuable source for drug development. But shouldn’t
one reconsider the utilization of ethnic/traditional
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and their combinations? Regulating traditional medicine
products, practices and practitioners is difficult due to
variations in definitions and categorizations of tradi-
tional medicine therapies. Evidence from clinical tests
done to evaluate the safety and effectiveness of tradi-
tional medicine products and practices is limited.
Requirements and methods for research and evaluation
are complex. For example, it can be difficult to assess
the quality of finished herbal products as the safety,
effectiveness and quality of the final product depends on
the quality of their source materials and the control of
the production processes. The quality and uniformity of
the chemical constituents and their concentrations in
natural products may be affected by factors such as sub-
species or age of plant, geographical and seasonal varia-
tions, time and method of collection and storage, etc.
Expanding the herbal materials market for products col-
lected from wild plant populations and cultivated medic-
inal plants could drive over-harvesting of plants and
threaten biodiversity. Efforts to preserve both plant
populations and knowledge on how to use them for
medicinal purposes is needed to sustain traditional med-
icine. In addition, domestication of prioritized plants in
combination with modern genetic engineering and agro
technological methods, could assure a sustained and
Table 1 Anti-malarial compounds from plants- recent reviews
Source Number of plant species or
compounds
Nature of compound Availability of chemical
structure
Quantitative toxicity tests
Tgaboto and Townson 2001
1
[36]
270 species extracts or purified
components
No No
Schwikkard and and van
Heerden 2002
2[37]
170 compounds purified Yes No
Saxena et al 2003
3[38] 250 compounds purified Yes Few
Frederich et al, 2008
4[39] 31 compounds purified Yes vitro, vivo, good selectivity
Pillay et al, 2008
5[40] 216 species and 24
compounds
extracts or purified
components
For purified compounds No
Batista et al, 2009
6[41] 60 species extracts or purified
components
for some vitro, vivo, many with good
selectivity
Kaur et al, 2009
7[42] 266 compounds purified Yes vitro, vivo, many with good
selectivity
Mariath et al, 2009
8[43] 198 species extracts No vitro, vivo
Bero et al, 2009
9[44] 301 compounds purified Yes vitro, vivo
1. Compiled a list of 270 plant species whose extracts or purified components have anti-malarial activity but no chemical structures or details about their
potency were provided.
2. A total of 170 structures have been reviewed from 186 references found in the literature up to December 2000.
3. Provides a critical account of crude extracts, essential oils and anti-plasmodial secondary metabolites with diverse chemical structures from higher plants,
covering the period 1993-2003. A total of 127 alkaloids, 18 quassinoids, 23 sesquiterpenes, 27 triterpenoids, 21 flavonoids/xanthones, nine quinones and 25
miscellaneous compounds were highlighted in their work, although very few quantitative details are provided.
4. Three ethnobotanical screening programmes have been conducted on South African plants while there have been a few studies adopting a more direct
approach, where plants within a particular genus were screened for anti-plasmodial activity. The paper also summarizes the bioactive molecules identified from
selected plants having anti-plasmodial activity.
5. Covers 31 indole alkaloids isolated from natural sources with high anti-plasmodial activity (in vitro and in vivo), most of them displaying IC50 values under the
micromolar range and with a good selectivity index.
6. Review anti-plasmodial non-alkaloids natural products from reports published in the period Jan/2008-May/2009. Compounds include the classes of terpenes,
limonoids, flavonoids, chromones, xanthones, anthraquinones, and other miscellaneous and related compounds .The review covers 60 plant species belonging to
34 families, some of them extracted by 3 different solvents. Twenty four extracts were found with significant activity, e.g., IC50<3 μg/ml. Some were also tested in
vivo. Most extracts show only weak activity in culture or in mouse models. Many recent reports on anti-plasmodial activity of plants used in local ethnic medicine
are, however, not reviewed.
7. Review focusing on anti-plasmodial compounds discovered during 1998-2008 from all natural sources, including crude extracts from plant and marine
organisms. A total of 266 anti-plasmodial natural products, for most the available chemical and pharmacological details are shown. The compounds listed in this
compilation belong to the classes of alkaloids, terpenes, quassinoids, flavonoids, limonoids, chalcones, peptides, xanthones, quinones, coumarins and
miscellaneous compounds, as well as 37 promising semisynthetic anti-malarials. The review also presents progress in recent semi-synthetic approaches to
develop drugs from natural sources which display some anti-malarial activity. The semi-synthetic compounds belong to different classes: alkaloids –
naphthylisoquinoline, bisbenzylisoquinoline, protoberberine, aporphine, indole alkaloids, manzamine alkaloids and others. Terpenes – sesquiterpenes, triterpenes,
diterpenes and others. Other semi-synthetic compounds belong to quassinoids, flavonoids, limonoids, chalcones, peptides, xanthones, quinones and coumarins.
For many of them, data on anti-plasmodial activity in culture and anti-malarial activity in mouse models and toxicity facts are provided. Most importantly, several
compounds containing unique structural composition have been isolated and characterized.
8. Review plants of the American continent with anti-malarial activity, describing 198 plants whose extracts were active in vitro and in vivo. In vivo tests were
done on P. berghei, P. gallinaceum, P. vinckei, P. lophurae, P. cathemerium and P. yoelii strains.
9. Review only compounds purified from plants used in traditional medicine, covering publications between 2005 and 2008. The list of compounds contains
flavonoid derivatives, xanthones, coumarins, lignans, tannins, diterpenes and triterpenes, steroids, and derivatives of ornithine, lysine, phenylalanine, tyrosine and
tryptophane derivatives, as well as steroidal alkaloids. Alkaloids and diterpenes are the most numerous among the highly active compounds (IC50 ≤2 μM), while
coumarins, steroids, stilbenes and tannins provide only moderate activity (2 < IC50 ≤ 11 μM). The Caesalpiniaceae family provides the highest number of highly
active compounds. But the Asteraceae, Leguminosae and Moraceae are significant contributors.
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contain the desired and expected amounts of pharmaco-
logically active constituents and their potentiators.
Achieving such goals could also provide additional
means of production to indigenous countries and self
sufficiency in antimalarial drugs when the present high
level of international support in the purchase and distri-
bution of modern drugs will dwindle with time.
How the use of traditional medicines is being
considered in practice?
WHO and its Member States are already cooperating to
promote the use of traditional medicine. The goals of
this collaboration are to support and integrate tradi-
tional medicine into national health systems in combi-
nation with national policy and regulation for products,
practices and providers; to ensure the safety and the
quality of the products and practices, based on available
evidence; to acknowledge traditional medicine as part of
primary health care; to preserve knowledge and
resources ensure patient safety by upgrading the skills
and knowledge of traditional medicine providers. What
seem to be overlooked, yet it should be very high on the
agenda, is the development of rigorous protocols for the
clinical testing of traditional remedies. Such tests should
consider anti-disease efficacy, toxicity, mutagenicity,
age- and pregnancy-dependent effects, antagonism or
synergism with presently used anti-malarials and survey
of possible evolution of resistance.
In parallel, the African Network for Drugs and Diag-
nostics Innovation (ANDI) has been recently launched
in Abuja in 2008 and established at the 2nd ANDI Sta-
keholders’ Meeting in 2009 in Cape Town, with the mis-
sion to promote and sustain African-led health product
innovation to address African public health needs
through the assembly of research networks and building
of capacity to support human and economic develop-
ment [33]. Health product innovation as used here cov-
ers the entire product R&D value chain, including new
drugs based on traditional medicines and natural pro-
ducts. Hopefully, these initiatives will result in the devel-
opment of indigenous means for chemotherapy and
prophylaxis of malaria at an affordable price and sus-
tainable efficacy. Relevant to this hope is the recently
updated FDA regulations for multicomponent botanical
therapeutics (“Guidance for Industry: Botanical Drug
Products,” published by the FDA Center for Drug Eva-
luation and Research in 2006 [34,35]). The guidance
provides an exemption for botanical drugs with some
prior history of human use, allowing them to advance
through phase II clinical trials with fewer preclinical and
toxicological studies than would be required for new
chemical entities. In addition, the guidance does not
require full characterization of all extract components
or full elucidation of their interactions, and may tolerate
some variation in the final composition of the botanical
drug.
Conclusions
In this short essay, the rationale for using natural com-
pounds for drug development has been presented with
specific consideration of anti-malarial drugs. The under-
lying principles for using drug combination and the ben-
efits of using multi-component plant extracts have been
argued. It seems that the scientific and pharmacological
justification of these principles could provide the basis
for further development of ethnic/traditional medicine
as a valid, cheap and locally-available means to treat
malaria.
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